BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31093876)

  • 1. The prognostic impact of hypermethylation for a panel of tumor suppressor genes and cell of origin subtype on diffuse large B-cell lymphoma.
    Shawky SA; El-Borai MH; Khaled HM; Guda I; Mohanad M; Abdellateif MS; Zekri AN; Bahanasy AA
    Mol Biol Rep; 2019 Aug; 46(4):4063-4076. PubMed ID: 31093876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma.
    Kristensen LS; Hansen JW; Kristensen SS; Tholstrup D; Harsløf LB; Pedersen OB; De Nully Brown P; Grønbæk K
    Clin Epigenetics; 2016; 8(1):95. PubMed ID: 27610206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas.
    Amara K; Trimeche M; Ziadi S; Laatiri A; Hachana M; Korbi S
    Ann Oncol; 2008 Oct; 19(10):1774-86. PubMed ID: 18539616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of E-cadherin and Runx3 in Helicobacter Pylori - Associated gastric carcinoma is achieved through regulating P21waf and P27 expression.
    Bahnassy AA; Helal TE; El-Ghazawy IM; Samaan GF; Galal El-Din MM; Abdellateif MS; Desouky E; Zekri AN
    Cancer Genet; 2018 Dec; 228-229():64-72. PubMed ID: 30553475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
    Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
    Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma.
    Kristensen LS; Asmar F; Dimopoulos K; Nygaard MK; Aslan D; Hansen JW; Ralfkiaer E; Grønbæk K
    Oncotarget; 2014 Oct; 5(20):9798-810. PubMed ID: 25229255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
    Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
    Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
    Nakamichi I; Tomita Y; Zhang B; Sugiyama H; Kanakura Y; Fukuhara S; Hino M; Kanamaru A; Ogawa H; Aozasa K
    Ann Hematol; 2007 Aug; 86(8):557-64. PubMed ID: 17508213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma.
    Huang W; Xue X; Shan L; Qiu T; Guo L; Ying J; Lu N
    BMC Cancer; 2017 Dec; 17(1):815. PubMed ID: 29202805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
    Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
    Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
    Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
    Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
    Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
    Montalbán C; Díaz-López A; Martín A; Baile M; Sanchez JM; Sancho JM; García O; Novelli S; Monter-Rovira A; Salar A; Bastos M; Gutiérrez A; Bento L; Córdoba R; Arquero T; González de Villambrosia S; Barranco G; De Oña R; López Guillermo A; Rodriguez Salazar MJ; Domínguez JF; Fernández R; Queizan JA; Rodríguez J; Abraira V; García JF;
    Br J Haematol; 2018 Aug; 182(4):534-541. PubMed ID: 29978453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylation of p15 gene in diffuse - large B-cell lymphoma: association with less aggressiveness of the disease.
    Krajnović M; Jovanović MP; Mihaljević B; Anđelić B; Tarabar O; Knežević-Ušaj S; Krtolica K
    Clin Transl Sci; 2014 Oct; 7(5):384-90. PubMed ID: 24815848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
    Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
    J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.